Fecal Microbiota Transplantation

Gastroenterology Clinics of North America

Volumn 46, Issue 1, 2017, Pages 171-185

  Vindigni, Stephen M ^a   Surawicz, Christina M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Fecal microbiota transplant; FMT; Microbiome; Stool transplant

Indexed keywords

LOPERAMIDE;

ABDOMINAL DISCOMFORT; BLOATING; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MEDICAL HISTORY; MICROBIOME; NAUSEA; NONHUMAN; RECURRENT INFECTION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VOMITING; CLOSTRIDIUM INFECTION; DONOR SELECTION; DYSBIOSIS; INFORMED CONSENT; PATIENT SELECTION; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DONOR SELECTION; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; INFLAMMATORY BOWEL DISEASES; INFORMED CONSENT; PATIENT SELECTION;

EID: 85011268701     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2016.09.012     Document Type: Review

References (56)

1. 1 Zhang, F., Luo, W., Shi, Y., et al. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol, 107, 2012, 1755 [author reply: 1755–6].
2. 2 Brandt, L.J., Aroniadis, O.C., Mellow, M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (2012), 1079–1087.
3. 3 Borody, T.J., Warren, E.F., Leis, S.M., et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 38:6 (2004), 475–483.
4. 4 Eiseman, B., Silen, W., Bascom, G.S., et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44:5 (1958), 854–859.
5. 5 Vindigni, S.M., Broussard, E.K., Surawicz, C.M., Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol 7:7 (2013), 615–628.
6. 6 Hamilton, M.J., Weingarden, A.R., Unno, T., et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4 (2013), 125–135.
7. 7 Khoruts, A., Dicksved, J., Jansson, J.K., et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44:5 (2010), 354–360.
8. 8 Gough, E., Shaikh, H., Manges, A.R., Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53 (2011), 994–1002.
9. 9 Kassam, Z., Lee, C.H., Yuan, Y., et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 108:4 (2013), 500–508.
10. 10 Food and Drug Administration Center for Biologics Evaluation and Research, Guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. 2013, Food and Drug Administration, Silver Spring (MD).
11. 11 Choi, H.H., Cho, Y.S., Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc 49:3 (2016), 257–265.
12. 12 Brandt, L.J., Aroniadis, O.C., An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 78:2 (2013), 240–249.
13. 13 OpenBiome, OpenBiome FMT capsule G3 clinical primer. 2016, OpenBiome, Medford (MA).
14. 14 Youngster, I., Russell, G.H., Pindar, C., et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312:17 (2014), 1772–1778.
15. 15 Lessa, F.C., Gould, C.V., McDonald, L.C., Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55:Suppl 2 (2012), S65–S70.
16. 16 Lessa, F.C., Community-associated Clostridium difficile infection: how real is it?. Anaerobe 24 (2013), 121–123.
17. 17 Khanna, S., Pardi, D.S., The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 4:4 (2010), 409–416.
18. 18 McFarland, L.V., Surawicz, C.M., Rubin, M., et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 20:1 (1999), 43–50.
19. 19 van Nood, E., Vrieze, A., Nieuwdorp, M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:5 (2013), 407–415.
20. 20 Cammarota, G., Masucci, L., Ianiro, G., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 41:9 (2015), 835–843.
21. 21 Kelly, C.R., Khoruts, A., Staley, C., et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. Ann Intern Med, 2016 [Epub ahead of print].
22. 22 Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:4 (2013), 478–498 [quiz: 499].
23. 23 Debast, S.B., Bauer, M.P., Kuijper, E.J., et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20:Suppl 2 (2014), 1–26.
24. 24 Youngster, I., Sauk, J., Pindar, C., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58:11 (2014), 1515–1522.
25. 25 Konijeti, G.G., Sauk, J., Shrime, M.G., et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 58:11 (2014), 1507–1514.
26. 26 Ott, S.J., Musfeldt, M., Wenderoth, D.F., et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53:5 (2004), 685–693.
27. 27 Frank, D.N., St Amand, A.L., Feldman, R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:34 (2007), 13780–13785.
28. 28 Fujimoto, T., Imaeda, H., Takahashi, K., et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol 28:4 (2013), 613–619.
29. 29 Sokol, H., Pigneur, B., Watterlot, L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:43 (2008), 16731–16736.
30. 30 Damman, C.J., Miller, S.I., Surawicz, C.M., et al. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?. Am J Gastroenterol 107 (2012), 1452–1459.
31. 31 Bennet, J.D., Brinkman, M., Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet, 1(8630), 1989, 164.
32. 32 Borody, T.J., George, L., Andrews, P., et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?. Med J Aust, 150(10), 1989, 604.
33. 33 Borody, T.J., Warren, E.F., Leis, S., et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 37:1 (2003), 42–47.
34. 34 Colman, R.J., Rubin, D.T., Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 8:12 (2014), 1569–1581.
35. 35 Anderson, J.L., Edney, R.J., Whelan, K., Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 36:6 (2012), 503–516.
36. 36 Vindigni, S.M., Zisman, T.L., Suskind, D.L., et al. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol 9:4 (2016), 606–625.
37. 37 Kassinen, A., Krogius-Kurikka, L., Makivuokko, H., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133:1 (2007), 24–33.
38. 38 Simren, M., Barbara, G., Flint, H.J., et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62:1 (2013), 159–176.
39. 39 Pinn, D.M., Aroniadis, O.C., Brandt, L.J., Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol 109:11 (2014), 1831–1832.
40. 40 Pinn, D.M., Aroniadis, O.C., Brandt, L.J., Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?. Neurogastroenterol Motil 27:1 (2015), 19–29.
41. 41 Nicholson, J.K., Holmes, E., Kinross, J., et al. Host-gut microbiota metabolic interactions. Science 336:6086 (2012), 1262–1267.
42. 42 Ley, R.E., Turnbaugh, P.J., Klein, S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 444:7122 (2006), 1022–1023.
43. 43 Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:7122 (2006), 1027–1031.
44. 44 Vrieze, A., Van Nood, E., Holleman, F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:4 (2012), 913–916.e7.
45. 45 Ananthaswamy, A., Faecal transplant eases symptoms of Parkinson's. New Sci, 209, 2011, 01.
46. 46 Borody, T., Leis, S., Campbell, J., et al. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol, 106, 2011, S352.
47. 47 Borody, T., Campbell, J., Torres, M., et al. Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. Am J Gastroenterol, 106, 2011, S352.
48. 48 Finegold, S.M., Molitoris, D., Song, Y., et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 35:Suppl 1 (2002), S6–S16.
49. 49 Kelly, C.R., Ihunnah, C., Fischer, M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109:7 (2014), 1065–1071.
50. 50 Agrawal, M., Aroniadis, O.C., Brandt, L.J., et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 50:5 (2016), 403–407.
51. 51 Vindigni, S.M., Surawicz, C.M., Stool transplant for the senior citizen: is it safe?. Maturitas 88 (2016), 23–24.
52. 52 Kelly, C.R., Kahn, S., Kashyap, P., et al. Update on Fecal Microbiota Transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149:1 (2015), 223–237.
53. 53 Petrof, E.O., Gloor, G.B., Vanner, S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome, 1(1), 2013, 3.
54. 54 McCune, V.L., Struthers, J.K., Hawkey, P.M., Faecal transplantation for the treatment of Clostridium difficile infection: a review. Int J Antimicrob Agents 43:3 (2014), 201–206.
55. 55 Bakken, J.S., Borody, T., Brandt, L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9 (2011), 1044–1049 United States: 2011 AGA Institute. Published by Elsevier Inc.
56. 56 Brandt, L.J., American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 108 (2013), 177–185.